Curtis Ashley F, Masellis Mario, Hsiung Ging-Yuek Robin, Moineddin Rahim, Zhang Kathy, Au Bonnie, Millett Geneva, Mackenzie Ian, Rogaeva Ekaterina, Tierney Mary C
From the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute (A.F.C., M.M., K.Z., M.C.T.), Primary Care Research Unit (A.F.C., K.Z., B.A., G.M., M.C.T.), and Cognitive & Movement Disorders Clinic (M.M.), Sunnybrook Health Sciences Center, Toronto; Division of Neurology (G.-Y.R.H.) and Department of Pathology and Laboratory Medicine (I.M.), University of British Columbia, Vancouver; Departments of Family and Community Medicine (R.M., M.C.T.) and Medicine (E.R.) and Tanz Centre for Research in Neurodegenerative Diseases (E.R.), University of Toronto; and Department of Neuropathology (I.M.), Vancouver General Hospital, Canada.
Neurology. 2017 Oct 10;89(15):1633-1642. doi: 10.1212/WNL.0000000000004494. Epub 2017 Sep 15.
To conduct a meta-analysis that investigates sex differences in the prevalence of mutations in the 3 most common genes that cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)-chromosome 9 open reading frame 72 (), progranulin (), or microtubule-associated protein tau ()-in patients clinically diagnosed with these conditions.
MEDLINE, EMBASE, and PsycINFO databases were searched (inception to June 30, 2016). Studies of patients with FTD or ALS that reported the number of men and women with and without mutations of interest were selected. Female to male pooled risk ratios (RR) and 95% confidence intervals (CI) for each mutation were calculated using random-effects models.
Thirty-two articles reporting 12,784 patients with ALS (including 1,244 mutation carriers) revealed a higher prevalence of female patients with related ALS (RR 1.16, 95% CI 1.04-1.29). Twenty-three articles reporting 5,320 patients with FTD (including 488 mutation carriers) revealed no sex differences in -related FTD (RR 0.95, 95% CI 0.81-1.12). Thirty-six articles reporting 3,857 patients with FTD (including 369 mutation carriers) revealed a higher prevalence of female patients with related FTD (RR 1.33, 95% CI 1.09-1.62). Finally, 21 articles reporting 2,377 patients with FTD (including 215 mutation carriers) revealed no sex difference in related FTD (RR 1.21, 95% CI 0.95-1.55).
Higher female prevalence of hexanucleotide repeat expansions in ALS and mutations in FTD suggest that sex-related risk factors might moderate and mediated phenotypic expression.
进行一项荟萃分析,研究在临床诊断为肌萎缩侧索硬化症(ALS)和额颞叶痴呆(FTD)的患者中,导致这两种疾病的3个最常见基因——9号染色体开放阅读框72(C9orf72)、原颗粒蛋白(GRN)或微管相关蛋白tau(MAPT)——突变发生率的性别差异。
检索MEDLINE、EMBASE和PsycINFO数据库(起始至2016年6月30日)。选择报告了有或无相关突变的男性和女性患者数量的FTD或ALS患者研究。使用随机效应模型计算每种突变的女性与男性合并风险比(RR)和95%置信区间(CI)。
32篇报告12784例ALS患者(包括1244例C9orf72突变携带者)的文章显示,携带C9orf72相关ALS的女性患者患病率更高(RR 1.16,95%CI 1.04 - 1.29)。23篇报告5320例FTD患者(包括488例C9orf72突变携带者)的文章显示,C9orf72相关FTD不存在性别差异(RR 0.95,95%CI 0.81 - 1.12)。36篇报告3857例FTD患者(包括369例GRN突变携带者)的文章显示,携带GRN相关FTD的女性患者患病率更高(RR 1.33,95%CI 1.09 - 1.62)。最后,21篇报告2377例FTD患者(包括215例MAPT突变携带者)的文章显示,MAPT相关FTD不存在性别差异(RR 1.21,95%CI 0.95 - 1.55)。
ALS中C9orf72六核苷酸重复扩增以及FTD中GRN突变的女性患病率较高,提示性别相关风险因素可能调节GRN并介导表型表达。